Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study

CY Cheah; D Belada; MA Fanale; A Janikova; MS Czucman; IW Flinn; AV Kapp; A Ashkenazi; S Kelley; GL Bray; S Holden; JF Seymour

Journal article

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study

CY Cheah, D Belada, MA Fanale, A Janikova, MS Czucman, IW Flinn, AV Kapp, A Ashkenazi, S Kelley, GL Bray, S Holden, JF Seymour

Lancet Haematology | Published : 2015

DOI: 10.1016/S2352-3026(15)00026-5

Abstract

Background Dulanermin—a non-polyhistidine-tagged soluble recombinant human apoptosis ligand 2 (Apo2L) or tumour-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)—has pro-apoptotic activity in a range of cancers and synergistic preclinical activity with rituximab against lymphoma in vivo. We aimed to assess the safety, pharmacokinetics, and efficacy of dulanermin and rituximab in patients with relapsed indolent B-cell non-Hodgkin lymphoma. Methods We did an open-label phase 1b/2 randomised study. Four study centres in the USA enrolled patients into phase 1b, and 27 study centres in the USA, Italy, Australia, France, Czech Republic, New Zealand, and Poland enrolled patients into phase ..

View full abstract

University of Melbourne Researchers

John Seymour Author

Grants

Funding Acknowledgements

This study was funded by Genentech (South San Francisco, CA, USA) and Amgen (Thousand Oaks, CA, USA). We thank the patients, carers, investigators, sub-investigators, and research nurses who participated in the study.